IL137056A0 - Erythropoietin derivatives - Google Patents

Erythropoietin derivatives

Info

Publication number
IL137056A0
IL137056A0 IL13705600A IL13705600A IL137056A0 IL 137056 A0 IL137056 A0 IL 137056A0 IL 13705600 A IL13705600 A IL 13705600A IL 13705600 A IL13705600 A IL 13705600A IL 137056 A0 IL137056 A0 IL 137056A0
Authority
IL
Israel
Prior art keywords
erythropoietin derivatives
erythropoietin
derivatives
Prior art date
Application number
IL13705600A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL137056(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL137056A0 publication Critical patent/IL137056A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL13705600A 1999-07-02 2000-06-28 Erythropoietin derivatives IL137056A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14225499P 1999-07-02 1999-07-02
US15022599P 1999-08-23 1999-08-23
US15154899P 1999-08-31 1999-08-31
US16615199P 1999-11-17 1999-11-17

Publications (1)

Publication Number Publication Date
IL137056A0 true IL137056A0 (en) 2001-06-14

Family

ID=27495518

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13705600A IL137056A0 (en) 1999-07-02 2000-06-28 Erythropoietin derivatives

Country Status (52)

Country Link
US (2) US6583272B1 (de)
EP (2) EP1839676A3 (de)
JP (2) JP3727009B2 (de)
KR (1) KR100593143B1 (de)
CN (2) CN1283664C (de)
AR (2) AR024625A1 (de)
AT (1) ATE370748T1 (de)
AU (1) AU736067B2 (de)
BG (1) BG65449B1 (de)
BR (2) BRPI0002276B8 (de)
CA (1) CA2310536C (de)
CO (1) CO5190661A1 (de)
CY (2) CY1107719T1 (de)
CZ (1) CZ299516B6 (de)
DE (3) DE60036053T2 (de)
DK (1) DK1064951T3 (de)
DO (1) DOP2000000030A (de)
EA (1) EA003777B1 (de)
ES (2) ES2289985T3 (de)
FR (2) FR2795734B1 (de)
GB (2) GB2393960C (de)
GC (1) GC0000197A (de)
GE (1) GEP20022804B (de)
GT (1) GT200000109A (de)
HK (2) HK1068354A1 (de)
HR (1) HRP20000436B1 (de)
HU (1) HU226233B1 (de)
ID (1) ID26447A (de)
IL (1) IL137056A0 (de)
IS (1) IS2492B (de)
IT (1) IT1318606B1 (de)
LU (1) LU91363I2 (de)
MA (1) MA26746A1 (de)
MX (1) MXPA00006547A (de)
MY (1) MY128500A (de)
NL (1) NL300289I9 (de)
NO (2) NO327043B1 (de)
NZ (1) NZ505454A (de)
OA (1) OA11442A (de)
PA (1) PA8497801A1 (de)
PE (1) PE20010297A1 (de)
PL (1) PL202758B1 (de)
PT (1) PT1064951E (de)
RS (1) RS49928B (de)
SG (1) SG92717A1 (de)
SI (1) SI1064951T1 (de)
SK (1) SK286301B6 (de)
SV (1) SV2002000120A (de)
TN (1) TNSN00147A1 (de)
TR (1) TR200001956A2 (de)
TW (1) TWI235667B (de)
UY (1) UY26228A1 (de)

Families Citing this family (225)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4336452B2 (ja) 1997-12-08 2009-09-30 メルク パテント ゲーエムベーハー 標的化免疫治療および一般の免疫刺激に対して有用である二量体融合タンパク質
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
BR9909583A (pt) * 1998-04-15 2002-01-15 Lexigen Pharm Corp Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) † 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
CA2412845C (en) * 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
ES2320101T3 (es) * 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha Eritropoyetina conjugada con mono-peg.
EP1345628B1 (de) * 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
CN100528235C (zh) * 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1234583A1 (de) 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-Konjugate des HGF-NK4
MXPA03008031A (es) * 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
PL206975B1 (pl) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
JP2005524612A (ja) * 2001-12-06 2005-08-18 ファイブローゲン、インコーポレーテッド 内因性エリスロポエチン（ｅｐｏ）を増加させる方法
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
AU2003218045A1 (en) 2002-03-11 2003-09-29 Ortho Mcneil Pharmaceutical, Inc Methods for shp1 mediated neuroprotection
WO2004003176A2 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
AU2003258518B2 (en) 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20050176627A1 (en) * 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
EP1539960B1 (de) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistente modifizierte interferon alpha polypeptide
BR0314106A (pt) 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Polipeptìdeos hasilados, especialmente eritropoietina hasilada
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
MXPA05006384A (es) * 2002-12-17 2005-08-29 Merck Patent Gmbh Anticuerpo humanizado (h14.18) del anticuerpo 14.18 de raton enlazado a gd2 y su fusion con il-2.
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004227937B2 (en) 2003-03-31 2007-09-20 Xencor, Inc Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
KR101227666B1 (ko) * 2003-05-12 2013-01-31 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 펩티드
NZ563042A (en) * 2003-05-12 2008-09-26 Affymax Inc Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
CA2525464A1 (en) * 2003-05-12 2004-11-25 Qun Yin Novel poly(ethylene glycol) modified compounds and uses thereof
BRPI0411155A (pt) 2003-05-12 2006-07-11 Affymax Inc composto que se liga a e ativa o receptor de eritropoietina, composição farmacêutica e seu uso
CA2527665A1 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
WO2005011587A2 (en) * 2003-07-30 2005-02-10 New Century Pharmaceuticls Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN1897959A (zh) * 2003-09-29 2007-01-17 沃伦药品公司 用于治疗和预防脓毒病和粘连形成的组织保护细胞因子
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
CA2549486C (en) * 2003-12-19 2015-04-14 F. Hoffmann-La Roche Ag Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
EP1548031A1 (de) * 2003-12-22 2005-06-29 Dubai Genetics FZ-LLC Naturidentischer Erythropoietin
EP1699821B1 (de) * 2003-12-31 2012-06-20 Merck Patent GmbH Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MIT VERBESSERTER PHARMAKOKINETIK
EP1756173B1 (de) * 2004-01-21 2019-04-03 Nektar Therapeutics Verfahren zur herstellung von propionsäureterminierten polymeren
CN101001866A (zh) * 2004-02-02 2007-07-18 Ambrx公司 经修饰的人类干扰素多肽和其用途
JP5191729B2 (ja) 2004-03-11 2013-05-08 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 還元的アミノ化によって製造される、ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7253650B2 (en) 2004-05-25 2007-08-07 International Business Machines Corporation Increase productivity at wafer test using probe retest data analysis
US20090005292A1 (en) * 2004-11-11 2009-01-01 Affymax, Inc. Novel Peptides that Bind to the Erythropoietin Receptor
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
RU2007132188A (ru) 2005-01-25 2009-03-10 Селл Терапьютикс, Инк. (Us) Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo
EP1848461A2 (de) * 2005-02-16 2007-10-31 Nektar Therapeutics Al, Corporation Konjugate einer epo-gruppierung und eines polymers
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
US20080096252A1 (en) * 2005-10-04 2008-04-24 Zamost Bruce L Production and purification of il-29
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
EP1937294A4 (de) * 2005-10-21 2009-11-04 Synageva Biopharma Corp Glykolierte und glykosylierte therapeutische proteine von geflügel
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2007100902A2 (en) * 2006-02-28 2007-09-07 Oligasis Corporation Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
US8546329B2 (en) 2006-03-22 2013-10-01 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
PL2054074T3 (pl) * 2006-08-04 2015-03-31 Prolong Pharmaceuticals Llc Zmodyfikowana erytropoetyna
US8497246B2 (en) * 2006-08-18 2013-07-30 Armagen Technologies, Inc. Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
JP2010510794A (ja) * 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
CL2008000278A1 (es) * 2007-02-02 2008-09-26 Amgen Inc Anticuerpo monoclonal anti-hepcidina humana; acido nucleico que lo codifica; vector y celula huesped; metodo de produccion; composicion que lo comprende; kit de inmunoensayo que lo comprende; metodo para diagnosticar y tratar un trastorno relacionado
WO2008137066A1 (en) * 2007-05-02 2008-11-13 The Board Of Regents Of The University Of Oklahoma Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
AR067536A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (de) 2007-11-15 2010-08-25 Amgen, Inc Wässrige formulierung von mit antioxidantien stabilisiertem erythropoese-stimulierendem protein zur parenteralen verabreichung
CN101959934B (zh) 2008-01-11 2012-12-12 塞瑞纳治疗公司 聚噁唑啉共聚物的多官能形式和包含它的药物组合物
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
EP2574628B1 (de) 2008-01-25 2015-05-20 Amgen Inc. Ferroportin-Antikörper und Verwendungsverfahren
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20100003238A1 (en) 2008-04-14 2010-01-07 Frost Gregory I Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
MX2010011717A (es) 2008-05-01 2010-11-30 Amgen Inc Anticuerpos anti-hepcidina y metodos de uso.
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
UA106731C2 (uk) 2008-09-26 2014-10-10 Амбркс, Інк. Модифіковані поліпептиди еритропоетину тварин та їх застосування
CN104922669A (zh) 2008-11-13 2015-09-23 通用医疗公司 用于通过调整bmp-6来调节铁稳态的方法和组合物
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
JP5873003B2 (ja) 2009-03-18 2016-03-01 アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． ＩｇＧデコイ受容体融合タンパク質の血液脳関門送達のための組成物および方法
WO2011012296A1 (en) 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Moveable chromatography column separator
WO2011024025A1 (en) * 2009-08-28 2011-03-03 Avesthagen Limited An erythropoietin analogue and a method thereof
KR101441768B1 (ko) 2009-09-17 2014-09-17 박스터 헬쓰케어 에스에이 히알루로니다아제 및 면역글로불린의 안정한 복합제제, 및 그 사용방법
BR112012006602A2 (pt) * 2009-09-23 2019-09-24 Biogenerix Ag processo para a purificação de eritropoetina humana recombinante (epo), epo assim purificada e composições farmacêutica compreendendo a mesma
EP2485761B1 (de) 2009-10-09 2019-02-27 Armagen, Inc. Verfahren und zusammensetzungen für erhöhte iduronat-2-sulfatase-aktivität im zns
WO2011050333A1 (en) 2009-10-23 2011-04-28 Amgen Inc. Vial adapter and system
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
BR112012027361A2 (pt) 2010-04-27 2021-04-27 Scil Technology Gmbh formulação mia/cd-rap estável.
EA024052B1 (ru) 2010-06-07 2016-08-31 Эмджен Инк. Устройство для доставки лекарственного средства
KR20130125753A (ko) 2010-07-20 2013-11-19 할로자임, 아이엔씨 항-히알루로난제 투여와 관련된 유해 부작용의 치료
PL2616101T3 (pl) 2010-09-14 2015-01-30 Hoffmann La Roche Sposób oczyszczania pegylowanej erytropoetyny
BR112013017573B1 (pt) 2011-02-02 2021-05-18 F. Hoffmann-La Roche Ag uso de um suporte de coluna de cromatografia, suporte de coluna de cromatografia e dispositivo para suportar coluna de cromatografia
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2831100C (en) 2011-03-31 2020-02-18 Mark Dominis Holt Vial adapter and system
PL2699293T3 (pl) 2011-04-20 2019-08-30 Amgen Inc. Urządzenie do wstrzykiwania automatycznego
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
EP3744371A1 (de) 2011-10-14 2020-12-02 Amgen, Inc Injektor und verfahren zur montage
SG11201401797TA (en) 2011-10-24 2014-09-26 Halozyme Inc Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US8486399B2 (en) 2011-12-02 2013-07-16 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase A activity in the CNS
ES2749620T3 (es) 2011-12-30 2020-03-23 Halozyme Inc Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
PT2833905T (pt) 2012-04-04 2018-08-06 Halozyme Inc Terapia de combinação com hialuronidase e um taxano dirigido a tumor
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
CA2884887C (en) 2012-11-21 2023-09-12 Amgen Inc. Drug delivery device including insertion member and reservoir
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CN105263514B (zh) 2013-03-15 2019-04-26 本质生命科学有限公司 抗铁调素抗体及其用途
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
US10850037B2 (en) 2013-03-22 2020-12-01 Amgen Inc. Injector and method of assembly
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
HUE052447T2 (hu) 2013-09-08 2021-04-28 Kodiak Sciences Inc A VIII. tényezõs zwitterionos polimer konjugációk
JP7086520B2 (ja) 2013-10-24 2022-06-20 アムジエン・インコーポレーテツド インジェクター及び組み立ての方法
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3139977B1 (de) 2014-05-07 2021-02-17 Amgen Inc. Autoinjektor mit stossabsorbierenden elementen
WO2015187799A1 (en) 2014-06-03 2015-12-10 Amgen Inc. Systems and methods for remotely processing data collected by a drug delivery device
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
PT3186281T (pt) 2014-08-28 2019-07-10 Halozyme Inc Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP6766040B2 (ja) 2014-10-14 2020-10-07 アムジエン・インコーポレーテツド 視覚および可聴インジケータを備える薬剤注射装置
CN107208076A (zh) 2014-10-17 2017-09-26 科达制药 丁酰胆碱酯酶两性离子聚合物缀合物
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
US11357916B2 (en) 2014-12-19 2022-06-14 Amgen Inc. Drug delivery device with live button or user interface field
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
WO2016138434A1 (en) 2015-02-27 2016-09-01 Amgen Inc. Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
ES2755717T3 (es) 2015-12-09 2020-04-23 Amgen Inc Autoinyector con tapa de señalización
RU2744860C2 (ru) 2015-12-30 2021-03-16 Кодиак Сайенсиз Инк. Антитела и их конъюгаты
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
DK3429663T3 (da) 2016-03-15 2020-09-28 Amgen Inc Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
ES2959783T3 (es) 2016-05-13 2024-02-28 Amgen Inc Conjunto de cubierta protectora de vial
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
PL3484911T3 (pl) 2016-07-15 2021-03-08 F. Hoffmann-La Roche Ag Sposób oczyszczania PEGylowanej erytropoetyny
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
US11752258B2 (en) 2017-02-17 2023-09-12 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
EP3592402A1 (de) 2017-03-07 2020-01-15 Amgen Inc. Nadeleinführung durch überdruck
EP3592404A1 (de) 2017-03-09 2020-01-15 Amgen Inc. Einführmechanismus für eine arzneimittelabgabevorrichtung
JP2020511499A (ja) 2017-03-20 2020-04-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
CA3052676A1 (en) 2017-03-28 2018-10-04 Amgen Inc. Plunger rod and syringe assembly system and method
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
WO2018226515A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CN111107870A (zh) 2017-06-22 2020-05-05 催化剂生物科学公司 经修饰的膜型丝氨酸蛋白酶1（mtsp-1）多肽及其使用方法
WO2018236619A1 (en) 2017-06-22 2018-12-27 Amgen Inc. REDUCING THE IMPACTS / IMPACTS OF ACTIVATION OF A DEVICE
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
ES2972207T3 (es) 2017-07-14 2024-06-11 Amgen Inc Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble
EP3655063A1 (de) 2017-07-21 2020-05-27 Amgen Inc. Gasdurchlässiges dichtelement für arzneimittelbehälter und verfahren zur montage
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MA49838A (fr) 2017-08-09 2020-06-17 Amgen Inc Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
MA50611A (fr) 2017-10-04 2020-08-12 Amgen Inc Adaptateur d'écoulement destiné à un dispositif d'administration de médicament
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
EP3694578A1 (de) 2017-10-09 2020-08-19 Amgen Inc. Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
US11305026B2 (en) 2017-11-03 2022-04-19 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
US20200261648A1 (en) 2017-11-06 2020-08-20 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019090303A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Fill-finish assemblies and related methods
MX2020004736A (es) 2017-11-10 2020-08-13 Amgen Inc Embolos para dispositivos de administracion de farmacos.
EP3710090A1 (de) 2017-11-16 2020-09-23 Amgen Inc. Türverriegelungsmechanismus für wirkstofffreisetzungsvorrichtung
CA3084486A1 (en) 2017-11-16 2019-05-23 Amgen Inc. Autoinjector with stall and end point detection
JP7410860B2 (ja) 2017-12-29 2024-01-10 エフ． ホフマン－ラ ロシュ アーゲー Ｐｅｇ化タンパク質組成物を提供するための方法
HRP20220388T1 (hr) 2017-12-29 2022-05-27 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
US20200323993A1 (en) 2017-12-29 2020-10-15 Hoffmann-La Roche Inc. Process for providing pegylated protein composition
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
EP3826701A1 (de) 2018-07-24 2021-06-02 Amgen Inc. Ausgabevorrichtung zur verabreichung von arzneimitteln
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
US20210228797A1 (en) 2018-07-31 2021-07-29 Amgen Inc. Fluid path assembly for a drug delivery device
DK3613486T3 (da) * 2018-08-24 2021-01-04 Uga Biopharma Gmbh Metode og anlæg til rengøring af epo og/eller et epo-derivat
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
IL281469B1 (en) 2018-09-28 2024-04-01 Amgen Inc Assembling a memory alloy ejector activation assembly for a drug delivery device
CN117159846A (zh) 2018-10-02 2023-12-05 安进公司 具有内部力传递的用于药物递送的注射系统
WO2020072846A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
EA202191038A1 (ru) 2018-10-15 2021-07-06 Эмджен Инк. Способ платформенной сборки для устройства доставки лекарственного средства
EP3866890A1 (de) 2018-10-15 2021-08-25 Amgen Inc. Medikamentenabgabevorrichtung mit dämpfungsmechanismus
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
AU2020263289A1 (en) 2019-04-24 2021-09-16 Amgen Inc. Syringe sterilization verification assemblies and methods
JP2022545227A (ja) 2019-08-23 2022-10-26 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
EP4041312A4 (de) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Verfahren zur behandlung einer augenstörung
US20230331798A1 (en) 2020-09-22 2023-10-19 Jecho Laboratories, Inc. Glycosylation-modified erythopoietin and use thereof
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
TW202309062A (zh) 2021-05-10 2023-03-01 日商凱依歐姆 生物科學股份有限公司 抗體組成物之純化方法
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
WO2023209074A1 (en) 2022-04-28 2023-11-02 Institut National de la Santé et de la Recherche Médicale Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en) 2022-11-02 2024-05-10 F. Hoffmann-La Roche Ag Method for producing glycoprotein compositions
CN116492448A (zh) * 2023-04-12 2023-07-28 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE741187T1 (de) * 1995-05-05 1997-04-30 Hoffmann La Roche Rekombinante Obesitäts-(OB)-Proteine
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) * 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
WO2000032772A2 (en) 1998-11-30 2000-06-08 Eli Lilly And Company Erythropoietic compounds
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative

Also Published As

Publication number Publication date
GC0000197A (en) 2006-03-29
CY2007021I1 (el) 2009-11-04
DE60036053D1 (de) 2007-10-04
TNSN00147A1 (fr) 2005-11-10
GB2393960C (en) 2012-08-29
BRPI0002276B8 (pt) 2021-05-25
FR07C0051I2 (fr) 2008-05-09
HUP0002553A3 (en) 2005-11-28
ID26447A (id) 2001-01-04
HU226233B1 (en) 2008-07-28
HK1033328A1 (en) 2001-08-24
ITMI20001479A1 (it) 2001-12-30
SG92717A1 (en) 2002-11-19
GB0016205D0 (en) 2000-08-23
GB2393960A (en) 2004-04-14
MA26746A1 (fr) 2004-12-20
HUP0002553A2 (en) 2001-03-28
GT200000109A (es) 2001-12-21
YU40700A (sh) 2003-12-31
US20030120045A1 (en) 2003-06-26
CA2310536A1 (en) 2001-01-02
PL202758B1 (pl) 2009-07-31
ITMI20001479A0 (it) 2000-06-30
SK286301B6 (en) 2008-07-07
FR2795734B1 (fr) 2005-09-30
ES2191511B1 (es) 2005-01-01
IS2492B (is) 2009-02-15
TWI235667B (en) 2005-07-11
KR100593143B1 (ko) 2006-06-26
IS5554A (is) 2001-01-02
NL300289I9 (nl) 2019-08-21
UY26228A1 (es) 2000-10-31
JP2001064300A (ja) 2001-03-13
GB2353281A (en) 2001-02-21
AR024625A1 (es) 2002-10-16
DE60036053T2 (de) 2008-01-03
EA200000607A1 (ru) 2001-02-26
AU736067B2 (en) 2001-07-26
GEP20022804B (en) 2002-09-25
GB2353281B (en) 2004-06-09
MXPA00006547A (es) 2004-10-28
PA8497801A1 (es) 2001-12-14
CN1283664C (zh) 2006-11-08
FR2795734A1 (fr) 2001-01-05
NO2009010I2 (no) 2014-06-02
BRPI0002276B1 (pt) 2019-05-14
CA2310536C (en) 2007-09-11
CN1184233C (zh) 2005-01-12
BG104570A (en) 2001-09-28
NO20003372L (no) 2001-01-03
CY2007021I2 (el) 2009-11-04
RS49928B (sr) 2008-09-29
SV2002000120A (es) 2002-01-31
PE20010297A1 (es) 2001-03-07
CZ20002386A3 (cs) 2002-04-17
IT1318606B1 (it) 2003-08-27
HRP20000436B1 (en) 2008-01-31
GB2393960B (en) 2004-08-04
CN1280137A (zh) 2001-01-17
DE122007000064I1 (de) 2008-01-03
NO327043B1 (no) 2009-04-06
CN1515590A (zh) 2004-07-28
DK1064951T3 (da) 2007-10-08
SI1064951T1 (sl) 2007-12-31
NO2009010I1 (no) 2009-05-25
OA11442A (fr) 2004-04-28
PL341187A1 (en) 2001-01-15
KR20010049676A (ko) 2001-06-15
EP1064951A3 (de) 2002-03-20
HK1068354A1 (en) 2005-04-29
HRP20000436A2 (en) 2001-06-30
JP2004155787A (ja) 2004-06-03
HU0002553D0 (en) 2000-08-28
NL300289I2 (nl) 2010-02-01
EP1064951A2 (de) 2001-01-03
EP1064951B1 (de) 2007-08-22
FR07C0051I1 (de) 2007-12-14
SK9872000A3 (en) 2002-06-04
EP1839676A3 (de) 2008-09-03
BR0002276A (pt) 2001-12-11
CY1107719T1 (el) 2010-07-28
DOP2000000030A (es) 2002-07-15
ES2191511A1 (es) 2003-09-01
DE122007000064I2 (de) 2010-03-25
ES2289985T3 (es) 2008-02-16
NZ505454A (en) 2001-12-21
DE10031839A1 (de) 2001-02-01
NL300289I1 (nl) 2007-11-01
ATE370748T1 (de) 2007-09-15
JP3727009B2 (ja) 2005-12-14
LU91363I2 (fr) 2007-11-12
CZ299516B6 (cs) 2008-08-20
CO5190661A1 (es) 2002-08-29
AU4274400A (en) 2001-01-04
LU91363I9 (de) 2018-12-31
MY128500A (en) 2007-02-28
AR055650A2 (es) 2007-08-29
TR200001956A2 (tr) 2001-01-22
EP1839676A2 (de) 2007-10-03
NO20003372D0 (no) 2000-06-28
GB0400086D0 (en) 2004-02-04
EA003777B1 (ru) 2003-08-28
PT1064951E (pt) 2007-09-10
BG65449B1 (bg) 2008-08-29
US6583272B1 (en) 2003-06-24

Similar Documents

Publication Publication Date Title
GC0000197A (en) Erythropoietin derivatives
GC0000196A (en) Erythropoietin derivatives
EG23817A (en) 4-Phenyl-pyridine derivatives
HUP0201535A2 (en) 5-cyano-2-aminopyrimidine derivatives
IL148167A0 (en) Amino-triazolopyridine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
IL145739A0 (en) 13-methyl-erythromycin derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
IL148837A0 (en) Isoxazolecarboxamide derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
GB0026485D0 (en) ›-Carboline derivatives
IL147636A0 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
IL150132A0 (en) Cyclopenteneone derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
IL145949A0 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
PL351407A1 (en) Thio-oxindole derivatives
ZA200003282B (en) Erythropoietin derivatives.
IL146282A0 (en) Thio-oxindole derivatives
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
HK1043987A1 (zh) 硫-羥吲衍生物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
PEL Intention of commissioner to extend period of protection

Free format text: PRODUCT NAME: METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

Extension date: 20210916

EXTG Extension of patent term granted

Extension date: 20210916

EXTE Period for filing application for extension order has been extended (section 64p.(4))
EXTH Patent extension order corrected (sect. 64p(2))

Extension date: 20210720

KB Patent renewed
EXTN Extension order renewed